Our Science

A scientific library for regenerative and cellular medicine.

CELLMEX examines regenerative medicine through cellular biology, molecular signalling, extracellular-vesicle science, translational research, clinical evidence and responsible scientific interpretation.

Enter the Scientific Library View Published Studies

Scientific Foundation

Regenerative medicine requires scientific depth

Regenerative medicine is not one therapy or one product category. It includes living cells, extracellular vesicles, soluble signalling molecules, growth factors, biomaterials and tissue-directed biological systems.

Each platform has a distinct composition, manufacturing method, proposed mechanism, pharmacological profile and level of clinical evidence.

CELLMEX therefore evaluates each technology separately and avoids treating terms such as stem cells, exosomes, extracellular vesicles, secretome and conditioned media as interchangeable.

Our scientific library is intended to provide patients, physicians, researchers and institutional partners with a structured explanation of these differences.

Scientific Library

Core areas of CELLMEX science

Each subject below will ultimately have its own dedicated scientific landing page containing more detailed biology, laboratory methods, clinical evidence and references.

Cellular Biology

MSC Biology

Mesenchymal stromal cells are heterogeneous, culture-expanded cells commonly isolated from bone marrow, adipose tissue, umbilical-cord tissue and other stromal sources.

Their proposed biological activity is increasingly associated with immunomodulatory and paracrine signalling rather than permanent replacement of damaged tissue.

Immune-cell interaction and inflammatory signalling
Secretion of cytokines, growth factors and vesicles
Support of tissue-repair environments
Source-, donor- and process-dependent variability
Established, emerging and investigational applications

Explore MSC Biology →

Cell-Free Biology

Exosome Biology

Exosomes are a subtype of small extracellular vesicle formed through the endosomal pathway and released when multivesicular bodies fuse with the cell membrane.

They may carry proteins, lipids, messenger RNA, microRNA and other molecular cargo between cells. Demonstrating that a preparation consists specifically of exosomes requires more than particle-size measurement alone.

Endosomal biogenesis and vesicle release
Molecular cargo and intercellular communication
Uptake by recipient cells
Isolation and purification limitations
Emerging clinical and drug-delivery research

Explore Exosome Biology →

Molecular Signalling

Growth Factors

Growth factors are signalling proteins that bind to cellular receptors and influence proliferation, migration, differentiation, survival, angiogenesis and extracellular-matrix activity.

Relevant examples may include EGF, FGF, VEGF, PDGF, HGF, IGF and members of the TGF-β family. Laboratory formulations require attention to concentration, stability, carrier systems, release kinetics and biological potency.

Receptor-mediated signalling
Tissue repair and wound-healing biology
Angiogenic and extracellular-matrix effects
Stability and controlled-delivery challenges
Recombinant, platelet-derived and secreted sources

Explore Growth Factors →

Cell-Free Biology

Secretome

The secretome is the complete group of biological substances released by cells into their surrounding environment under defined culture conditions.

It may contain soluble proteins, cytokines, chemokines, growth factors, metabolites, nucleic acids and extracellular vesicles. Its composition changes according to cell source, passage, culture medium, oxygen level and cellular stress.

Soluble and vesicular components
Culture-condition and donor variability
Immunomodulatory and trophic signalling
Concentration and formulation strategies
Emerging cell-free therapeutic research

Explore Secretome Science →

Vesicle Science

Extracellular Vesicles

Extracellular vesicles are membrane-bound particles naturally released by cells. Broad categories include small extracellular vesicles, larger microvesicle-type particles and other membrane-enclosed structures.

They are studied as mediators of cell-to-cell communication, biomarkers, drug-delivery systems and possible cell-free therapeutic platforms.

EV nomenclature and subpopulation limitations
Separation, concentration and purification
Particle number, size and morphology
Protein markers and contaminant assessment
Functional and potency testing

Explore Extracellular Vesicles →

Translational Science

Mechanisms of Action

Mechanism-of-action research examines how a biological product interacts with cells, tissues, immune pathways and molecular systems to produce a measurable effect.

For regenerative technologies, the mechanism may involve several overlapping processes rather than one single molecular target.

Immune modulation
Paracrine and vesicular signalling
Angiogenic support
Anti-apoptotic and cytoprotective effects
Matrix remodelling and tissue-support pathways

Explore Mechanisms of Action →

Mechanisms of Action

How regenerative platforms may influence biology

The relative importance of each pathway depends on the product, cell source, manufacturing process, dose, administration route, tissue environment and medical indication.

Immunomodulation

Cellular and secreted products may influence macrophages, T cells, B cells, dendritic cells, natural-killer cells and inflammatory cytokine networks.

Paracrine Signalling

Cells may affect neighbouring tissues by releasing soluble proteins, lipids, metabolites and vesicles rather than by permanently engrafting.

Angiogenic Support

Signals involving VEGF, angiopoietins and other mediators may support endothelial-cell activity and microvascular remodelling.

Cytoprotection

Anti-apoptotic and stress-response pathways may help protect cells exposed to inflammatory, ischaemic or metabolic injury.

Matrix Remodelling

Biological mediators may influence collagen, proteoglycans, matrix metalloproteinases and the organisation of extracellular tissue structure.

Endogenous Repair Signalling

Some products may alter the local tissue environment in ways that support resident progenitor cells and intrinsic repair pathways.

Clinical Evidence

Not every regenerative application has the same evidence status

Established in Defined Uses

Haematopoietic Stem-Cell Transplantation

Blood-forming stem-cell transplantation is an established medical treatment for defined haematological malignancies, bone-marrow failure syndromes, immune disorders and selected inherited diseases.

Emerging Evidence

MSC-Based Clinical Applications

MSC products have been studied in immune, inflammatory, musculoskeletal, vascular and tissue-repair settings. Outcomes vary materially according to indication and product characteristics.

Predominantly Investigational

Exosomes, EVs and Secretome Products

These cell-free platforms are supported by substantial laboratory and preclinical research, but many clinical applications still require standardised manufacturing, potency testing and larger controlled trials.

Published Studies

Selected peer-reviewed scientific literature

This initial library includes reviews, systematic analyses and translational studies relevant to the CELLMEX technology portfolio. Inclusion does not mean that CELLMEX endorses every conclusion or that the publication proves a treatment is clinically effective.

MSC Mechanisms

The critical role of apoptosis in mesenchymal stromal cell therapeutics

Giacomini C, et al. 2023. PubMed PMID: 37185486.

Reviews evidence that MSC therapeutic activity may depend partly on recipient-mediated clearance and immune responses to apoptotic MSCs. It also discusses the mixed efficacy observed across clinical studies.

View on PubMed →

MSC and EV Biology

Mesenchymal stromal cells and their extracellular vesicles in regenerative medicine

2023 review. PubMed PMID: 37670393.

Summarises MSC characteristics, extracellular vesicle biology and proposed mechanisms involved in immunomodulation and tissue-support responses.

View on PubMed →

Clinical Evidence

Systematic review and meta-analysis of clinical trials using extracellular-vesicle therapies

Van Delen M, et al. 2024. PubMed PMID: 38958077.

Reviews regenerative, immunosuppressive and immunostimulatory EV studies. The authors note encouraging results but substantial heterogeneity in manufacturing, study design and adverse-event reporting.

View on PubMed →

EV Clinical Trials

Global trends of exosome applications in clinical trials

Rahnama M, et al. 2024. PubMed PMID: 39340738.

Examines the development of exosome-related clinical trials and the range of therapeutic fields in which extracellular-vesicle products are being investigated.

View on PubMed →

Secretome Science

Mesenchymal stem-cell secretome for regenerative medicine

Trigo CM, et al. PubMed PMID: 38729561.

Reviews soluble and vesicular components of the MSC secretome and discusses research involving respiratory, hepatic and neurological conditions.

View on PubMed →

Secretome Delivery

Stem-cell secretome delivery systems

Umar AK, et al. 2023. PMC10278206.

Examines stability limitations of secretome components and delivery strategies intended to improve localisation, protection and controlled biological release.

View Full Text →

Tissue Engineering

Therapeutic potential of MSC-derived exosomes in skin, bone and cartilage repair

Roszkowski S, et al. 2024. PubMed PMID: 38427086.

Reviews preclinical evidence involving wound healing, bone regeneration and cartilage repair, while identifying continuing translational challenges.

View on PubMed →

Growth-Factor Delivery

Hydrogel-based growth-factor delivery platforms

2023 review. PubMed PMID: 37009859.

Discusses biomaterial systems designed to protect growth factors and control their spatial and temporal release in regenerative applications.

View on PubMed →

Growth-Factor Biology

Epidermal growth factor in wound healing and regenerative medicine

2023 review. PubMed PMID: 36928481.

Reviews EGF biology, wound-related applications and the formulation challenges created by limited stability during storage and administration.

View on PubMed →

Exosome Reporting

Standardised reporting of research on exosomes

Yadav A, et al. 2024. PubMed PMID: 38888007.

Discusses inconsistencies in exosome preparations and the need for improved isolation, characterisation, reporting and clinical standardisation.

View on PubMed →

Video Library

Scientific education in visual format

This section is reserved for professionally produced CELLMEX educational videos, laboratory explanations, physician discussions and research presentations.

▶

How MSCs Communicate with Tissues

Proposed video explaining paracrine signalling, immune interaction and why MSC activity is not limited to cell differentiation.

▶

Exosomes and Extracellular Vesicles

Proposed animation distinguishing exosomes, small EVs, secretome and conditioned-media preparations.

▶

Inside the CELLMEX Laboratory

Proposed laboratory video covering culture, processing, analytical characterisation, quality controls and product handling.

White Papers and Scientific Standards

Consensus documents and technical guidance

The following resources provide scientific, methodological, ethical or regulatory context relevant to cellular and extracellular-vesicle research.

International Society for Extracellular Vesicles

MISEV2023

The current Minimal Information for Studies of Extracellular Vesicles guidance covering nomenclature, collection variables, EV separation, characterisation, functional studies and reporting.

Review MISEV2023 →

International Society for Stem Cell Research

Guidelines for Stem Cell Research and Clinical Translation

International guidance addressing scientific integrity, ethical oversight, cell procurement, research governance and responsible clinical translation.

Review ISSCR Guidelines →

International Society for Cellular Therapy

Minimal Criteria for Multipotent Mesenchymal Stromal Cells

Foundational criteria addressing plastic adherence, defined surface-marker expression and in-vitro differentiation characteristics used in MSC research.

Review the ISCT Criteria →

United States Food and Drug Administration

Regenerative-Medicine Patient and Consumer Information

Regulatory and patient-safety information concerning stem-cell, exosome and other regenerative-medicine products marketed without appropriate authorisation.

Review FDA Information →

CELLMEX Technical Library

MSC Product Identity and Characterisation

Reserved for a CELLMEX white paper defining cell source, donor qualification, culture process, identity markers, viability, sterility, potency and release criteria.

White Paper in Development →

CELLMEX Technical Library

Distinguishing Exosomes, Small EVs, Secretome and Conditioned Media

Reserved for a CELLMEX technical paper explaining differences in identity, isolation, composition, characterisation, potency and clinical positioning.

White Paper in Development →

Scientific Qualification

Responsible interpretation of regenerative science

Scientific information is not a treatment recommendation

Publications and laboratory findings describe research conducted using specific products, manufacturing methods, doses, routes of administration and patient populations. Results cannot automatically be applied to a different preparation or clinical setting.

Preclinical evidence, mechanistic plausibility and small uncontrolled studies do not provide the same level of evidence as properly designed controlled clinical trials.

CELLMEX scientific content should therefore identify whether an application is established, emerging or investigational and should not promise clinical benefit where reliable evidence is insufficient.

Continue Exploring

Connect the science to the technology platform

Review the individual CELLMEX technologies and learn how each platform differs in composition, manufacturing, characterisation and potential application.

Explore Our Technologies Research Collaboration